Patents by Inventor Rene Bernard

Rene Bernard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240382499
    Abstract: The invention relates to an inducer of senescence, in combination with a short-lived, selective Death Receptor 5 (DR5) agonist, for use in a method of treating a patient suffering from a tumor. The invention further relates to a pharmaceutical composition, comprising a short-lived, selective Death Receptor 5 (DR5) agonist and, optionally, an inducer of senescence. The invention further relates to methods of treating a patient having a tumor, and to a selective, short-lived DR5 agonist, for use in a method of selectively killing senescent cells, including senescent cancer cells.
    Type: Application
    Filed: January 17, 2022
    Publication date: November 21, 2024
    Inventors: Rene BERNARDS, Liqin WANG
  • Publication number: 20240282986
    Abstract: Disclosed is a method for controlling a pressure regulating valve (6) for regulating the internal pressure (Pint) of a fluid circuit (3) in an electrochemical device (2), said fluid circuit (3) being fed by a compressor (4) drawing air at an external pressure (Pext) and compressing same at the internal pressure (Pint) according to a compression ratio (A); said method comprises a step of measuring the external pressure (Pext), determining an internal pressure set point (Pint*) on the basis of the external pressure (Pext) measured and the compression range (B), so as to promote overall efficiency (R1) of the electrochemical device (2) and the compressor (4) according to the internal pressure (Pint) and the compression ratio (A), and a step of controlling the pressure regulating valve (6) so as to reach the internal pressure set point (Pint*).
    Type: Application
    Filed: May 31, 2022
    Publication date: August 22, 2024
    Applicant: SAFRAN POWER UNITS
    Inventors: Kilian Frank, Claude BERNARD, Robin Jacques, Marie VIALET, Olivier Rafaël, René CRASSOUS, Rémi André, Armand STEPHAN
  • Publication number: 20230310418
    Abstract: This invention provides compositions of (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, checkpoint kinase 1 (“CHK1”) inhibitor, B-cell lymphoma-extra large (“BCL-xL”) inhibitor, BCL-xL proteolysis-targeting chimera (“BCL-xL PROTAC”), pan-BCL inhibitor or ataxia telangiectasia and Rad3-related (“ATR”) inhibitor. This invention further provides methods for treating cancer or for preventing, inhibiting, or reducing risk of metastasis of a cancer, such as colorectal cancer, cholangiocarcinoma, pancreatic cancer or ovarian cancer, using (a) LB-100 or an LB-100 ester, or a pharmaceutically acceptable salt thereof, and (b) a WEE1 kinase inhibitor, CHK1 inhibitor, BCL-xL inhibitor, BCL-xL PROTAC, pan-BCL inhibitor or ATR inhibitor.
    Type: Application
    Filed: January 3, 2023
    Publication date: October 5, 2023
    Inventors: John S. KOVACH, Rene BERNARDS, Matheus Henrique DIAS
  • Publication number: 20220280499
    Abstract: The invention relates to a method of treating a patient suffering from a carcinoma, especially a hepatocellular carcinoma. The methods of the invention employ a specific combination of two protein kinase inhibitors, comprising lenvatinib and an Epidermal Growth Factor Receptor (EGFR) inhibitor. The invention further relates to a pharmaceutical preparation comprising lenvatinib and an EGFR inhibitor, a kit of parts, comprising lenvatinib and an EGFR inhibitor, and to the use of the pharmaceutical preparation or the kit of parts in a method of treating a patient suffering from a hepatocellular carcinoma.
    Type: Application
    Filed: October 21, 2020
    Publication date: September 8, 2022
    Inventors: Rene BERNARDS, Haojie JIN
  • Patent number: 10864179
    Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: December 15, 2020
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Liqin Wang, Rodrigo Leite De Oliveira, Rene Bernards
  • Patent number: 10398696
    Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 3, 2019
    Assignee: STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
    Inventors: Chong Sun, Rene Bernards
  • Publication number: 20180305768
    Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 25, 2018
    Applicants: The Netherlands Cancer Institute, Merck Sharp & Dohme Corp.
    Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
  • Publication number: 20180280324
    Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.
    Type: Application
    Filed: September 8, 2016
    Publication date: October 4, 2018
    Inventors: Liqin WANG, Rodrigo LEITE DE OLIVEIRA, Rene BERNARDS
  • Patent number: 9909185
    Abstract: The present invention relates to genetic markers whose expression is correlated with breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate clinical conditions associated with breast cancer, such as the presence or absence of the estrogen receptor ESR1, and BRCA1 and sporadic tumors, and to provide information on the likelihood of tumor distant metastases within five years of initial diagnosis. The invention relates to methods of using these markers to distinguish these conditions. The invention also relates to kits containing ready-to-use microarrays and computer software for data analysis using the statistical methods disclosed herein.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 6, 2018
    Assignees: THE NETHERLANDS CANCER INSTITUTE, MERCK SHARP & DOHME CORP.
    Inventors: HongYue Dai, Yudong He, Peter S. Linsley, Mao Mao, Christopher J. Roberts, Laura Johanna Van't Veer, Marc J. Van de Vijver, Rene Bernards, A.A. M. Hart
  • Publication number: 20180051346
    Abstract: The invention relates to methods and means of typing a sample from a breast cancer patient, preferably an invasive lobular breast cancer patient. The invention further relates to methods of assigning treatment to a patient suffering from invasive lobular breast cancer, and to methods of treating a patient suffering from invasive lobular breast cancer.
    Type: Application
    Filed: March 17, 2016
    Publication date: February 22, 2018
    Inventors: Tycho Bismeijer, Magali Michaut, Rene Bernards, Lodewyk Frederik Ary Wessels
  • Publication number: 20170292162
    Abstract: The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 12, 2017
    Applicant: Agendia N.V.
    Inventors: Tian Sun, Paul Roepman, Annuska Maria Glas, Rene Bernards, Iris Simon
  • Publication number: 20160319367
    Abstract: The invention relates to a method of predicting whether a breast cancer patient is or becomes resistant to anti-estrogen directed therapy. More specifically, the invention relates to methods and means for typing of breast cancer cells as having a good or a poor outcome to anti-estrogen directed therapy. The invention further relates to methods of assigning therapy to a breast cancer patient.
    Type: Application
    Filed: December 17, 2014
    Publication date: November 3, 2016
    Inventors: Rene Bernards, Sander Valentijn Maria Canisius, Willem Teunis Zwart, Eleonore Marielle Hijmans, Hendrika Maria Oosterkamp
  • Publication number: 20160186269
    Abstract: The invention relates to methods for determining the presence or absence of striatin-anaplastic lymphoma kinase (STRN-ALK) gene fusion and/or a Fibroblast Growth Factor Receptor 3—transforming acidic coiled-coil containing protein 3 (FGFR3-TACC3) gene fusion in an individual, especially an individual suffering from lung cancer. The invention further relates to a method for diagnosing an individual as having adenocarcinoma, and to a method for treating said individual. The invention additionally relates to a method for diagnosing an individual as having squamous cell carcinoma, and to a method for treating said individual.
    Type: Application
    Filed: May 27, 2014
    Publication date: June 30, 2016
    Inventors: Rene Bernards, Ian Jordan Majewski, Lorenza Mittempergher
  • Publication number: 20160022680
    Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to method of treatment these certain types of cancer. In particular, the disclosure relates to the combined use of inhibitors of MEK, EGFR and ERBB2 in the treatment of KRAS-mutant lung cancer, and KRAS-mutant colon cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: Chong SUN, Rene BERNARDS
  • Publication number: 20150275306
    Abstract: The present invention relates to methods of typing a sample from an individual suffering from cancer. The invention further relates to methods for assigning treatment to an individual suffering from cancer, comprising typing a sample from an individual suffering from cancer according to the methods of the invention.
    Type: Application
    Filed: October 10, 2013
    Publication date: October 1, 2015
    Inventors: Rene Bernards, Paul Roepman, Sidong Huang
  • Patent number: 8969544
    Abstract: The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from the group of an inhibitor of HDAC (an HDACi) and a retinoid.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: March 3, 2015
    Inventors: René Bernards, Mirjam Epping, Liming Wang
  • Publication number: 20140296248
    Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a lung cancer patient, wherein a reduced expression of a MEDIATOR and/or SW1/SNF complex gene in the lung cancer cells of the patient indicates that the lung cancer cells in the patient may be resistant to treatment with a receptor tyrosine kinase inhibitor, such as gefitinib and/or erlotinib. In some embodiments, the invention relates to methods and related compositions for predicting resistance to anticancer treatment by detecting the expression levels of one or more TGF-beta pathway nucleic acids and/or proteins.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 2, 2014
    Applicant: Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis
    Inventors: Rene Bernards, Sidong Huang, Michael Holzel
  • Publication number: 20140287931
    Abstract: The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in. a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a breast cancer patient, wherein a reduced expression of a MEDIATOR and/or SWI/SNF complex gene in the breast cancer cells of the patient indicates that the breast cancer cells in the patient may be successfully treated with a PI3K and/or mTOR inhibitor.
    Type: Application
    Filed: April 4, 2012
    Publication date: September 25, 2014
    Applicant: Stichting het Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis
    Inventors: Rene Bernards, Sidong Huang, Michael Holzel, Katrien Berns
  • Patent number: 8613462
    Abstract: A collapsible hitched trailer comprised of a bed member having a center bed section, and two pivotable bed sections pivotally attached to opposite sides of the center bed section. A protracting wheel axle member attached to an underside of the center bed section. Two wheels, one attached to each opposite end of the wheel axle member, and a draw bar member attached to one of the two pivotable bed sections, wherein the hitched trailer can be folded into a smaller shape and stored in a smaller area.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 24, 2013
    Inventor: Rene Bernard
  • Patent number: D864032
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 22, 2019
    Assignee: REMORQUES APOGÉE INC.
    Inventor: René Bernard